Effects of oat β-glucan consumption at breakfast on ad libitum eating, appetite, glycemia, insulinemia and GLP-1 concentrations in healthy subjects

Appetite. 2018 Sep 1:128:197-204. doi: 10.1016/j.appet.2018.06.019. Epub 2018 Jun 18.

Abstract

There is evidence that oat β-glucan lowers appetite and ad libitum eating; however, not all studies are consistent, and the underpinning mechanisms are not entirely understood. We investigated the effects of 4 g high molecular weight (MW) oat β-glucan on ad libitum eating, subjective appetite, glycemia, insulinemia and plasma GLP-1 responses in 33 normal-weight subjects (22 female/11 male, mean age (y): 26.9 ± 1.0, BMI (kg/m2): 23.5 ± 0.4). The study followed a randomised double-blind, cross-over design with subjects fed two test breakfasts with and without oat β-glucan followed by an ad libitum test meal on two different days. Blood samples and ratings for subjective appetite were collected postprandially at regular time intervals. Oat β-glucan increased feelings of fullness (p = 0.048) and satiety (p = 0.034), but did not affect energy and amount eaten at the ad libitum test meal. There was a treatment by time interaction for plasma GLP-1, plasma insulin and blood glucose. GLP-1 was significantly reduced at 90 min (p = 0.021), blood glucose at 30 min (p = 0.008) and plasma insulin at 30 and 60 min (p = 0.002 and 0.017, respectively) following the oat β-glucan breakfast when compared with the control breakfast. Four grams of high MW oat β-glucan lowers appetite but not ad libitum eating and beneficially modulates postprandial glycaemia, it does however, not increase plasma GLP-1 secretion.

Keywords: Energy intake; GLP-1; Glucose; Insulin; Oat β-glucan; Satiety.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Appetite / drug effects*
  • Avena*
  • Blood Glucose / metabolism
  • Breakfast / physiology*
  • Cross-Over Studies
  • Double-Blind Method
  • Eating / drug effects*
  • Female
  • Glucagon-Like Peptide 1 / blood
  • Healthy Volunteers
  • Humans
  • Insulin / blood
  • Male
  • Postprandial Period
  • Satiation / drug effects
  • beta-Glucans / administration & dosage*

Substances

  • Blood Glucose
  • Insulin
  • beta-Glucans
  • Glucagon-Like Peptide 1